Advertisement

Valvular Heart Failure

  • Madalina GarbiEmail author
Chapter

Abstract

Valvular heart failure is heart failure due to primary valvular heart disease or complicated by secondary valvular heart disease. This chapter describes the aetiological classification, prevalence, pathophysiology, diagnosis and management of valvular heart failure, including heart transplantation and mechanical circulatory support.

Keywords

Valvular heart failure Valve disease related heart failure HFpEF aortic stenosis HFrEF aortic stenosis HFpEF mitral regurgitation HFrEF mitral regurgitation 

References

  1. 1.
    Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Marciniak A, Glover K, Sharma R. Cohort profile: prevalence of valvular heart disease in community patients with suspected heart failure in UK. BMJ Open. 2017;7(1):e012240.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    d’Arcy JL, Coffey S, Loudon MA, Kennedy A, Pearson-Stuttard J, Birks J, Frangou E, Farmer AJ, Mant D, Wilson J, Myerson SG, Prendergast BD. Large-scale community echocardiographic screening reveals a major burden of undiagnosed valvular heart disease in older people: the OxVALVE Population Cohort Study. Eur Heart J. 2016;37(47):3515–22.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Călin A, Roşca M, Beladan CC, Enache R, Mateescu AD, Ginghină C, Popescu BA. The left ventricle in aortic stenosis—imaging assessment and clinical implications. Cardiovasc Ultrasound. 2015;13:22.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Elahi MM, Chuang A, Ewing MJ, Choi CH, Grant PW, Matata BM. One problem two issues! Left ventricular systolic and diastolic dysfunction in aortic stenosis. Ann Transl Med. 2014;2(1):10.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Dweck MR, Joshi S, Murigu T, Alpendurada F, Jabbour A, Melina G, Banya W, Gulati A, Roussin I, Raza S, Prasad NA, Wage R, Quarto C, Angeloni E, Refice S, Sheppard M, Cook SA, Kilner PJ, Pennell DJ, Newby DE, Mohiaddin RH, Pepper J, Prasad SK. Midwall fibrosis is an independent predictor of mortality in patients with aortic stenosis. J Am Coll Cardiol. 2011;58:1271–9.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Dweck MR, Boon NA, Newby DE. Calcific aortic stenosis a disease of the valve and the myocardium. J Am Coll Cardiol. 2012;60:1854–63.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Garbi M, MacCarthy P, Shah AM, Chambers JB. Classical and paradoxical low-flow low-gradient aortic stenosis: a heart failure perspective. Struct Heart. 2018;2(1):3–9.  https://doi.org/10.1080/24748706.2017.1384876.CrossRefGoogle Scholar
  9. 9.
    Herrmann S, Störk S, Niemann M, Lange V, Strotmann JM, Frantz S, Beer M, Gattenlöhner S, Voelker W, Ertl G, Weidemann F. Low-gradient aortic valve stenosis myocardial fibrosis and its influence on function and outcome. J Am Coll Cardiol. 2011;58:402–12.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Pibarot P, Dumesnil JG. Low-flow, low gradient aortic stenosis with normal and depressed left ventricular ejection fraction. J Am Coll Cardiol. 2012;60:1845–53.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Dahl JS, Eleid MF, Pislaru SV, Scott CG, Connolly HM, Pellikka PA. Development of paradoxical low-flow, low-gradient severe aortic stenosis. Heart. 2015;101:1015–23.  https://doi.org/10.1136/heartjnl-2014-306838.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Chambers J. Low “gradient”, low flow aortic stenosis. Heart. 2006;92:554–8.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Awtry E, Davidoff R. Low-flow/low-gradient aortic stenosis. Circulation. 2011;124:e739–41.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Zaid RR, Barker CM, Little SH, Nagueh SF. Pre- and post-operative diastolic dysfunction in patients with valvular heart disease: diagnosis and therapeutic implications. J Am Coll Cardiol. 2013;62:1922–30.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Starling MR, Kirsh MM, Montgomery DG, Gross MD. Mechanisms for left ventricular systolic dysfunction in aortic regurgitation: importance for predicting the functional response to aortic valve replacement. J Am Coll Cardiol. 1991;17:887–97.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Gaasch WH, Meyer TE. Left ventricular response to mitral regurgitation implications for management. Circulation. 2008;118:2298–303.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Ahmed MI, Guichard JL, Soorappan RN, Ahmad S, Mariappan N, Litovsky S, Gupta H, Lloyd SG, Denney TS, Powell PC, Aban I, Collawn J, Davies JE, McGiffin DC, Dell’Italia LJ. Disruption of desmin-mitochondrial architecture in patients with regurgitant mitral valves and preserved ventricular function. J Thorac Cardiovasc Surg. 2016;152(4):1059–1070.e2.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Lee R, Marwick TH. Assessment of subclinical left ventricular dysfunction in asymptomatic mitral regurgitation. Eur J Echocardiogr. 2007;8:175–84.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Quintana E, Suri RM, Thalji NM, Daly RC, Dearani JA, Burkhart HM, Li Z, Enriquez-Sarano M, Schaff HV. Left ventricular dysfunction after mitral valve repair—the fallacy of “normal” preoperative myocardial function. J Thorac Cardiovasc Surg. 2014;148:2752–62.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Darby AE, DiMarco JP. Management of atrial fibrillation in patients with structural heart disease. Circulation. 2012;125:945–57.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Magne J, Pibarot P, Sengupta PP, Donal E, Rosenhek R, Lancellotti P. Pulmonary hypertension in valvular disease: a comprehensive review on pathophysiology to therapy from the HAVEC Group. J Am Coll Cardiol Img. 2015;8:83–99.CrossRefGoogle Scholar
  22. 22.
    Barbieri A, Bursi F, Grigioni F, Tribouilloy C, Avierinos JF, Michelena HI, Rusinaru D, Szymansky C, Russo A, Suri R, Bacchi Reggiani ML, Branzi A, Modena MG, Enriquez-Sarano M, on behalf of the Mitral Regurgitation International DAtabase (MIDA) Investigators. Prognostic and therapeutic implications of pulmonary hypertension complicating degenerative mitral regurgitation due to flail leaflet: a multicenter long-term international study. Eur Heart J. 2011;32:751–9.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Malouf JF, Enriquez-Sarano M, Pellikka PA, Oh JK, Bailey KR, Chandrasekaran K, Mullany CJ, Tajik AJ. Severe pulmonary hypertension in patients with severe aortic valve stenosis: clinical profile and prognostic implications. J Am Coll Cardiol. 2002;40:789–95.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Ennezat PV, Sylvestre Maréchaux S, Pibarot P, Le Jemtel TH. Secondary mitral regurgitation in heart failure with reduced or preserved left ventricular ejection fraction. Cardiology. 2013;125:110–7.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Breithardt OA, Sinha AM, Schwammenthal E, Bidaoui N, Markus KU, Franke A, Stellbrink C. Acute effects of cardiac resynchronization therapy on functional mitral regurgitation in advanced systolic heart failure. J Am Coll Cardiol. 2003;41:765–70.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Asgar AW, Mack MJ, Stone GW. Secondary mitral regurgitation in heart failure: pathophysiology, prognosis, and therapeutic considerations. J Am Coll Cardiol. 2015;65:1231–48.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Dreyfus GD, Martin RP, Chan KMJ, Dulguerov F, Alexandrescu C. Functional tricuspid regurgitation: a need to revise our understanding. J Am Coll Cardiol. 2015;65:2331–6.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Muraru D, Surkova E, Badano LP. Revisit of functional tricuspid regurgitation; current trends in the diagnosis and management. Korean Circ J. 2016;46(4):443–55.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Ring L, Dutka DP, Wells FC, Fynn SP, Shapiro LM, Rana BS. Mechanisms of atrial mitral regurgitation: insights using 3D transoesophageal echo. Eur Heart J Cardiovasc Imaging. 2014;15:500–8.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Lancellotti P, Garbi M. Progression of secondary mitral regurgitation: from heart failure to valvular heart failure. Eur Heart J Cardiovasc Imaging. 2018;19(6):613–4.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Bartko PE, Pavo N, Pérez-Serradilla A, Arfsten H, Neuhold S, Wurm R, Lang IM, Strunk G, Dal-Bianco JP, Levine RA, Hülsmann M, Goliasch G. Evolution of secondary mitral regurgitation. Eur Heart J Cardiovasc Imaging. 2018;19(6):622–9.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Clavel MA, Burwash IG, Pibarot P. Cardiac imaging for assessing low-gradient severe aortic stenosis. J Am Coll Cardiol Img. 2017;10:185–202.CrossRefGoogle Scholar
  33. 33.
    Grayburn PA, Carabello B, Hung J, Gillam LD, Liang D, Mack MJ, McCarthy PM, Miller DC, Trento A, Siegel RJ. Defining “severe” secondary mitral regurgitation: emphasizing an integrated approach. J Am Coll Cardiol. 2014;64:2792–801.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28:1–39.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Myerson SG, d’Arcy J, Christiansen JP, Dobson LE, Mohiaddin R, Francis JM, Prendergast B, Greenwood JP, Karamitsos TD, Neubauer S. Determination of clinical outcome in mitral regurgitation with cardiovascular magnetic resonance quantitation. Circulation. 2016;133:2287–96.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Myerson SG, d’Arcy J, Mohiaddin R, Greenwood JP, Karamitsos TD, Francis JM, Banning AP, Christiansen JP, Neubauer S. Aortic regurgitation quantification using cardiovascular magnetic resonance: association with clinical outcome. Circulation. 2012;126:1452–6.PubMedCrossRefGoogle Scholar
  37. 37.
    Pandis D, Sengupta PP, Castillo JG, Caracciolo G, Fischer GW, Narula J, Anyanwu A, Adams DH. Assessment of longitudinal myocardial mechanics in patients with degenerative mitral valve regurgitation predicts postoperative worsening of left ventricular systolic function. J Am Soc Echocardiogr. 2014;27:627–38.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Vinereanu D, Ionescu AA, Fraser AG. Assessment of left ventricular long axis contraction can detect early myocardial dysfunction in asymptomatic patients with severe aortic regurgitation. Heart. 2001;85:30–6.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Pierard LA, Lancellotti P. Stress testing in valve disease. Heart. 2007;93:766–72.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Wahi S, Haluska B, Pasquet A, Case C, Rimmerman CM, Marwick TM. Exercise echocardiography predicts development of left ventricular dysfunction in medically and surgically treated patients with asymptomatic severe aortic regurgitation. Heart. 2000;84:606–14.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Lancellotti P, Pellikka PA, Budts W, Chaudhry FA, Donal E, Dulgheru R, Edvardsen T, Garbi M, Ha JW, Kane GC, Kreeger J, Mertens L, Pibarot P, Picano E, Ryan T, Tsutsui JM, Varga A. The clinical use of stress echocardiography in nonischaemic heart disease: recommendations from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging. 2016;17:1191–229.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T, Flachskampf FA, Gillebert TC, Klein AL, Lancellotti P, Marino P, Oh JK, Popescu BA, Waggoner AD. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29(4):277–314.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Podlesnikar T, Delgado V, Bax JJ. Cardiovascular magnetic resonance imaging to assess myocardial fibrosis in valvular heart disease. Int J Cardiovasc Imaging. 2018;34(1):97–112.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Chin CWL, Everett RJ, Kwiecinski J, Vesey AT, Yeung E, Esson G, Jenkins W, Koo M, Mirsadraee S, White AC, Japp AG, Prasad SK, Semple S, Newby DE, Dweck MR. Myocardial fibrosis and cardiac decompensation in aortic stenosis. JACC Cardiovasc Imaging. 2017;10(11):1320–33.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Edwards NC, Moody WE, Yuan M, Weale P, Neal D, Townend JN, Steeds RP. Quantification of left ventricular interstitial fibrosis in asymptomatic chronic primary degenerative mitral regurgitation. Circ Cardiovasc Imaging. 2014;7:946–53.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Uretsky S, Gillam LD. Myocardial fibrosis in asymptomatic degenerative mitral regurgitation: what does T1 mapping tell us? Circ Cardiovasc Imaging. 2014;7:860–2.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M, Aboyans V, Vaz Carneiro A, Achenbach S, Agewall S, Allanore Y, Asteggiano R, Paolo Badano L, Albert Barberà J, Bouvaist H, Bueno H, Byrne RA, Carerj S, Castro G, Erol Ç, Falk V, Funck-Brentano C, Gorenflo M, Granton J, Iung B, Kiely DG, Kirchhof P, Kjellstrom B, Landmesser U, Lekakis J, Lionis C, Lip GY, Orfanos SE, Park MH, Piepoli MF, Ponikowski P, Revel MP, Rigau D, Rosenkranz S, Völler H, Zamorano JL. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67–119.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Sharma V, Stewart RA, Lee M, Gabriel R, Van Pelt N, Newby DE, Kerr AJ. Plasma brain natriuretic peptide concentrations in patients with valvular heart disease. Open Heart. 2016;3(1):e000184.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Parikh V, Kim C, Siegel RJ, Arsanjani R, Rader F. Natriuretic peptides for risk stratification of patients with valvular aortic stenosis. Circ Heart Fail. 2015;8:373–80.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Clavel MA, Malouf J, Michelena HI, Suri RM, Jaffe AS, Mahoney DW, Enriquez-Sarano M. B-type natriuretic peptide clinical activation in aortic stenosis: impact on long-term survival. J Am Coll Cardiol. 2014;63(19):2016–25.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Clavel MA, Tribouilloy C, Vanoverschelde JL, Pizarro R, Suri RM, Szymanski C, Lazam S, Oberti P, Michelena HI, Jaffe A, Enriquez-Sarano M. Association of B-type natriuretic peptide with survival in patients with degenerative mitral regurgitation. J Am Coll Cardiol. 2016;68(12):1297–307.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    McCarthy CP, Donnellan E, Phelan D, Griffin BP, Enriquez-Sarano M, McEvoy JW. High sensitivity troponin and valvular heart disease. Trends Cardiovasc Med. 2017;27(5):326–33.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Lancellotti P, Dulgheru R, Magne J, Henri C, Servais L, Bouznad N, Ancion A, Martinez C, Davin L, Le Goff C, Nchimi A, Piérard L, Oury C. Elevated plasma soluble ST2 is associated with heart failure symptoms and outcome in aortic stenosis. PLoS One. 2015;10(9):e0138940.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Iung B, Lancellotti P, Lansac E, Muñoz DR, Rosenhek R, Sjögren J, Mas PT, Vahanian A, Walther T, Wendler O, Windecker S, Zamorano JL, ESC Scientific Document Group. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2017;38(36):2739–91.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, O’Gara PT, Ruiz CE, Skubas NJ, Sorajja P, Sundt TM 3rd, Thomas JD. 2014 AHA/ACC guidelines for the management of patients with valvular heart disease. J Am Coll Cardiol. 2014;63:e57–185.PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Fleisher LA, Jneid H, Mack MJ, McLeod CJ, O’Gara PT, Rigolin VH, Sundt TM 3rd, Thompson A. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135(25):e1159–95.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Khot UN, Novaro GM, Popović ZB, Mills RM, Thomas JD, Tuzcu EM, Hammer D, Nissen SE, Francis GS. Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med. 2003;348(18):1756–63.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Lindman BR, Bonow RO, Otto CM. Current management of calcific aortic stenosis. Circ Res. 2013;113:223–37.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Gertz ZM, Raina A, Saghy L, Zado ES, Callans DJ, Marchlinski FE, Keane MG, Silvestry FE. Evidence of atrial functional mitral regurgitation due to atrial fibrillation: reversal with arrhythmia control. J Am Coll Cardiol. 2011;58:1474–81.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Ypenburg C, Lancellotti P, Tops LF, Bleeker GB, Holman ER, Piérard LA, Schalij MJ, Bax JJ. Acute effects of initiation and withdrawal of cardiac resynchronization therapy on papillary muscle dyssynchrony and mitral regurgitation. J Am Coll Cardiol. 2007;50:2071–7.PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Herrmann HC, Pibarot P, Hueter I, Gertz ZM, Stewart WJ, Kapadia S, Tuzcu EM, Babaliaros V, Thourani V, Szeto WY, Bavaria JE, Kodali S, Hahn RT, Williams M, Miller DC, Douglas PS, Leon MB. Predictors of mortality and outcomes of therapy in low-flow severe aortic stenosis: a placement of aortic transcatheter valves (PARTNER) trial analysis. Circulation. 2013;127:2316–26.PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Feldman T, Foster E, Glower DG, Kar S, Rinaldi MJ, Fail PS, Smalling RW, Siegel R, Rose GA, Engeron E, Loghin C, Trento A, Skipper ER, Fudge T, Letsou GV, Massaro JM, Mauri L, for the EVEREST II Investigators. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med. 2011;364(15):1395–406.PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Whitlow PL, Feldman T, Pedersen WR, Lim DS, Kipperman R, Smalling R, Bajwa T, Herrmann HC, Lasala J, Maddux JT, Tuzcu M, Kapadia S, Trento A, Siegel RJ, Foster E, Glower D, Mauri L, Kar S, EVEREST II Investigators. Acute and 12-month results with catheter-based mitral valve leaflet repair: the EVEREST II (endovascular valve edge-to-edge repair) high risk study. J Am Coll Cardiol. 2012;59(2):130–9.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Maisano F, Alfieri O, Banai S, Buchbinder M, Colombo A, Falk V, Feldman T, Franzen O, Herrmann H, Kar S, Kuck KH, Lutter G, Mack M, Nickenig G, Piazza N, Reisman M, Ruiz CE, Schofer J, Søndergaard L, Stone GW, Taramasso M, Thomas M, Vahanian A, Webb J, Windecker S, Leon MB. The future of transcatheter mitral valve interventions: competitive or complementary role of repair vs. replacement? Eur Heart J. 2015;36(26):1651–9.PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Guerrero M, Dvir D, Himbert D, Urena M, Eleid M, Wang DD, Greenbaum A, Mahadevan VS, Holzhey D, O’Hair D, Dumonteil N, Rodés-Cabau J, Piazza N, Palma JH, DeLago A, Ferrari E, Witkowski A, Wendler O, Kornowski R, Martinez-Clark P, Ciaburri D, Shemin R, Alnasser S, McAllister D, Bena M, Kerendi F, Pavlides G, Sobrinho JJ, Attizzani GF, George I, Nickenig G, Fassa AA, Cribier A, Bapat V, Feldman T, Rihal C, Vahanian A, Webb J, O’Neill W. Transcatheter mitral valve replacement in native mitral valve disease with severe mitral annular calcification: results from the first multicenter global registry. JACC Cardiovasc Interv. 2016;9(13):1361–71.PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    Muller DW, Farivar RS, Jansz P, Bae R, Walters D, Clarke A, Grayburn PA, Stoler RC, Dahle G, Rein KA, Shaw M, Scalia GM, Guerrero M, Pearson P, Kapadia S, Gillinov M, Pichard A, Corso P, Popma J, Chuang M, Blanke P, Leipsic J, Sorajja P, Tendyne Global Feasibility Trial Investigators. Transcatheter mitral valve replacement for patients with symptomatic mitral regurgitation: a global feasibility trial. J Am Coll Cardiol. 2017;69(4):381–91.PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Feldman T, Young A. Percutaneous approaches to valve repair for mitral regurgitation. J Am Coll Cardiol. 2014;63:2057–68.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Stehlik J, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dipchand AI, Dobbels F, Kirk R, Rahmel AO, Hertz MI, for the International Society of Heart and Lung Transplantation. The registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report—2012. J Heart Lung Transplant. 2012;31(10):1052–64.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Czer LS, Goland S, Soukiasian HJ, Gallagher S, De Robertis MA, Mirocha J, Siegel RJ, Kass RM, Trento A. Aortic valve replacement or heart transplantation in patients with aortic stenosis and severe left ventricular dysfunction. Transplant Proc. 2013;45(1):364–8.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Kawajiri H, Manlhiot C, Ross H, Delgado D, Billia F, McDonald M, Rao V. High-risk cardiac surgery as an alternative to transplant or mechanical support in patients with end-stage heart failure. J Thorac Cardiovasc Surg. 2017;154(2):517–25.PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Fischer S, Glas K. A review of cardiac transplantation. Anesthesiol Clin. 2013;31:383–403.PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Tjang YS, van der Heijden GJ, Tenderich G, Körfer R, Grobbee DE. Long-term results of heart transplantation for end-stage valvular heart disease. J Card Surg. 2009;24(5):580–4.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Wang TS, Hernandez AF, Felker GM, Milano CA, Rogers JG, Patel CB. Valvular heart disease in patients supported with left ventricular assist devices. Circ Heart Fail. 2014;7(1):215–22.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Royal Papworth Hospital, Cambridge Biomedical CampusCambridgeUK

Personalised recommendations